C4 Therapeutics (NASDAQ:CCCC – Get Free Report)‘s stock had its “buy” rating reissued by Stifel Nicolaus in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $13.00 target price on the stock, up from their previous target price of $12.00. Stifel Nicolaus’ target price would suggest a potential […]
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have been given an average rating of “Hold” by the seven research firms that are presently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year […]
C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) – Equities researchers at Brookline Capital Management issued their FY2028 earnings estimates for shares of C4 Therapeutics in a research note issued to investors on Tuesday, January 9th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of $47.11 for the year. […]
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) and ZIVO Bioscience (NASDAQ:ZIVO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Risk and Volatility C4 Therapeutics has a […]
C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 8,100,000 shares, a growth of 330.9% from the November 30th total of 1,880,000 shares. Based on an average daily volume of 11,739,900 shares, the days-to-cover ratio […]